Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website.

Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
Vaccination status among patients with the need for emergency hospitalizations related to COVID-19

İbrahim Toker a,*, Ayşin Kılıç Toker b, Ayşe Turunç Özdemir b, İlhami Çelik b, Oğuzhan Bol a, Emre Bülbül c

a Department of Emergency Medicine, University of Health Sciences Kayseri City Training and Research Hospital, Kayseri, Turkey
b Department of Infectious Disease and Clinical Microbiology, University of Health Sciences Kayseri City Training and Research Hospital, Kayseri, Turkey
c Department of Emergency Medicine, Erciyes University, Faculty of Medicine, Kayseri, Turkey

A R T I C L E   I N F O

Article history:
Received 10 December 2021
Received in revised form 28 January 2022
Accepted 29 January 2022

Keywords:
COVID-19 vaccines
Emergency medicine
Hospitalization
Mortality

A B S T R A C T

Background: It is thought vaccines allowed for emergency use significantly reduce hospitalizations and emergency room visits. It is a matter of curiosity how many of the patients who come to the emergency department (ED) are vaccinated. We aimed to examine the characteristics of ED patients needing hospitalizations related to moderate and severe COVID-19 by vaccination status.

Methods: A retrospective study of 559 rRT-PCR-confirmed SARS-CoV-2 infection cases with moderate or severe COVID-19 needing hospitalization was performed in August 2021. Univariate and multivariate logistic regression analyses were performed for factors associated with mortality.

Results: The mean age of the patients was 60.8 ± 18.1 years old, and 54.2% (n = 303) of the patients were women. The most common comorbidities were hypertension (37.2%), diabetes mellitus (31.1%) and chronic obstructive pulmonary disease (13.8%), respectively. The number of patients with alpha variant was 399 (71.4%), and delta variant was 83 (14.8%). Fifty point 6% (n = 283) of the patients were fully vaccinated. The total number of patients who died in the study was 114 (20.4%), and the number of patients hospitalized in the intensive care unit was 168 (30.1%). The day between the last dose of vaccine and hospitalization was 117 ± 45.9 days. In multivariate regression analyses, age, vaccination status, comorbidities and the male gender were associated with mortality. Our study did not evaluate the vaccine efficacy but, a lower mortality rate was observed in those fully vaccinated with CoronaVac and Pfizer–BioNTech. Additionally, Alpha, Delta and other variants had the same mortality rates.

1. Introduction

Since the pandemics started worldwide, as of Sept 14, 2021, there have been over 4 million deaths and over 200 million confirmed cases of coronavirus disease 2019 (COVID-19) reported to WHO. As of Sept 12, 2021, more than 5 billion vaccine doses have been administered worldwide [1]. Inactivated whole virion (CoronaVac) and BNT162b2 mRNA (Pfizer–BioNTech) severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines have demonstrated high efficacy against symptomatic disease in phase 3 clinical trials [2,3]. A study of nationwide national surveillance data in Israel reported that two doses of the Pfizer–BioNTech vaccine significantly reduced hospitalizations and emergency department (ED) visits for all age groups [4]. In the light of these studies, it is essential to examine the real-world effects of COVID-19 vaccines [5].

We aimed to examine the characteristics of ED patients needing hospitalization related to moderate and severe COVID-19 by vaccination status.

2. Method

2.1. Study design and patients

We conducted a retrospective analysis of hospitalized COVID-19 patients in the ED of an urban teaching hospital, with a bed capacity of
In August 2021, a total of 2371 patients were admitted to our ED with the suspicion of COVID-19. All those patients arrived by ambulance at the ED. Five hundred ninety-six of these patients were hospitalized with a preliminary diagnosis of COVID-19. Five hundred sixty-six patients were PCR confirmed, and there were seven patients whose vaccine information could not be reached. As a result, a total of 559 rRT-PCR-conﬁrmed SARS-CoV-2 infections, moderate or severe COVID-19 cases, according to the NIH disease severity categories, were included in the study [6] (Fig. 1). The patients with mild illness may display various signs and symptoms (e.g., fever, cough, sore throat, malaise, headache, muscle pain, nausea, vomiting, diarrhea, loss of taste and smell). The patients do not have dyspnea, shortness of breath with exertion, or abnormal imaging. Moderate illness is deﬁned as evidence of lower respiratory disease during clinical assessment or imaging, with SpO2 ≥ 94% on the room. The patients with COVID-19 are considered to have severe illness if they have SpO2 < 94% on room air, PaO2 /FiO2 < 300 mmHg, a respiratory rate > 30 breaths/min, or lung inﬁltrates >50% [6]. A total of 1775 patients were considered mild because they did not have shortness of breath, exertional dyspnea, and abnormal imaging. A nasopharyngeal swab test was performed on these patients, and the first treatment of these patients is arranged in the ED, and they are referred to the pandemic outpatient clinics for follow-up.

2.2. Hospitalization criteria

Bio-Speedy® SARS-CoV-2 Emerging Plus kit (Bioeksen, Istanbul, Turkey) test was used in the SARS-CoV-2 PCR test on nasopharyngeal swabs to determine the presence of SARS-CoV-2 infection. Bio-Speedy® SARS-CoV-2 Emerging Plus kit Delta (B.1.617.2 and all AY lineages), Alpha (B.1.1.7 and all Q. lineages), Gamma (P.1), Mu (B. 1.621) variants can be determined.

According to the National Institutes of Health (NIH) severity of illness categories, rRT-PCR-conﬁrmed SARS-CoV-2 infection cases with moderate or severe COVID-19 patients were included in the study [6].

Data on age, gender, comorbid conditions, and vaccination status were recorded. Patients had three groups by vaccination 1) not vaccinated (never vaccinated, and patients who received only one dose of any COVID-19 vaccine 14 days before hospitalization) 2) partially vaccinated (1 dose of CoronaVac or Pfizer-BioNTech ≥14 days before hospital admission or two doses, second dose ≤14 days before hospital admission) 3) fully vaccinated (both doses given); the second dose of CoronaVac or Pfizer-BioNTech ≥14 days before hospital admission. Total hospital stays until hospital outcome (death or discharge) was calculated.

2.3. Sample size estimation

To perform sample size calculation, we viewed data from preliminary results from our study. The sample size was calculated using Medcalc software with a power of $\alpha = 0.05$ and 80%, based on the assumption that 25% of hospitalized patients would be fully vaccinated. And the mortality rate would be 25% in unvaccinated patients and 12.5% (50% reduction) in vaccinated patients. The required sample size was 500, and 559 patients were included in our study.

2.4. Statistical analysis

In the study's statistical analysis, categorical data were assessed frequency and percentage. Also, the continuous data were evaluated as a mean, standard deviation or median (minimum-maximum) value based on the data distribution. The Shapiro-Wilk test was used to control the normality of continuous measurements. Descriptive statistics for categorical variables was performed using the Chi-square test, while an independent sample t-test /Mann Whitney U was used for continuous data. Univariate and multivariate logistic regression analyses were applied for factors associated with in-hospital mortality. In-hospital mortality was assessed at any time, with a minimum of 1 and a maximum of 59 days. The crude and adjusted odds ratios (ORs) and 95% conﬁdence intervals (CIs) were estimated. The level of signiﬁcance (p-value) was considered to be 0.05.

2.5. Ethical approval

This study was approved by the ethics committee of XXX City Hospital (Approval No. 18112021/ 518). The signed informed consent was exempted due to the retrospective character of the research.

---

Fig. 1. Flowchart for patient selection.
3. Results

3.1. Patient characteristics

A total of 559 patients were included in the study. The mean age of the patients was 60.8 ± (18.1) (min:16, max:102), and 54.2% (n = 303) of the patients were women. 49.6% (n = 277) of the patients were 65 years or older. There was at least one comorbidity in 65.1% (n = 364) of the patients. The most common comorbidities were hypertension (37.2%), diabetes mellitus (31.1%) and chronic obstructive pulmonary disease (13.8%), respectively. The number of patients with alpha variant was 399 (71.4%), and the number of patients with delta variant was 83 (14.8%), 50.6% (n = 283) of the patients were fully vaccinated. The total number of patients who died in the study was 114 (20.4%), and the number of patients hospitalized in the intensive care unit was 168 (30.1%). The day between the last dose of vaccine and hospitalization was 117 ± 45.9 days. There was no statistically significant difference between genders regarding mortality (p = 0.101). While the mean age of non-survivors was 67.4 ± 14.4 years, that of survivors was 59.2 ± 18.6 years, which was statistically significant (p < 0.001). The age group with 65 years and older showed a significant difference of 62.3% than fewer 65 years old (p < 0.001). There was no significant difference between variants in mortality (p = 0.208). There was a statistically significant difference in mortality between the fully vaccinated and unvaccinated groups (36.8% vs. 57%, p < 0.001). Fully vaccinated patients were divided into groups regarding the time between the last dose of vaccination and hospitalization. There was no statistically significant difference between the group over 120 days and 14–120 days (p = 0.118). Other clinical features of the patients are shown in Table 1.

There was a statistically significant difference between the groups 65 years and older versus 65 years fewer in vaccination status (p < 0.001). In particular, the rate of unvaccinated patients under 65 years was significantly higher than that of patients aged 65 and over (63.1% vs. 17%). The vaccination status by two age groups is shown in Table 2.

3.2. Univariate and multivariate logistic regression analysis for mortality

In univariate analysis, age, over 65 years of age, comorbid diseases, partial and full vaccination status were associated with mortality. In multivariate logistic regression analysis: age (odds ratio (OR), 1.05; 95% confidence intervals (95% CI) 1.03–1.08-year increase), male gender (OR, 1.8; 95% CI, 1.1–2.9), presence of comorbid diseases (OR, 2; 95% CI, 1.1–3.7) and partial (OR, 0.24; 95% CI, 0.09–0.6) and fully vaccination status (OR, 0.1; 95% CI, 0.05–0.18) were associated with mortality among COVID-19 patients. The results of multivariable regression analysis are presented in Table 3.

Table 1
Baseline characteristics of patients.

|                        | Total          | Survived       | Died           | p-Value       |
|------------------------|----------------|----------------|----------------|---------------|
| Age in years, Mean (± SD) | 60.8 ± 18.1    | 59.2 ± 18.6    | 67.4 ± 14.4    | <0.001*       |
| Age groups             |                |                |                |               |
| < 65y                  | 282 (50.4%)    | 239 (53.7%)    | 43 (37.7%)     | 0.002         |
| ≥ 65 y                 | 277 (49.6%)    | 206 (46.3%)    | 71 (62.3%)     |               |
| Sex distribution       |                |                |                |               |
| Female                 | 303 (54.2%)    | 249 (56%)      | 54 (47.4%)     | 0.101         |
| Male                   | 256 (45.8%)    | 196 (44%)      | 60 (52.6%)     |               |
| Variants               |                |                |                |               |
| Alpha (B.1.1.7)        | 399 (71.4%)    | 310 (69.7%)    | 89 (78.1%)     | 0.208         |
| Delta (B.1.617.2)      | 83 (14.8%)     | 70 (15.7%)     | 13 (11.4%)     |               |
| Others'                | 77 (13.8%)     | 65 (14.6%)     | 12 (10.5%)     |               |
| Vaccination status     |                |                |                |               |
| Not vaccinated         | 225 (40.3%)    | 160 (36%)      | 65 (57%)       | <0.001        |
| Partially vaccinated   | 51 (9.1%)      | 44 (9.9%)      | 7 (6.1%)       |               |
| Fully vaccinated       | 283 (50.6%)    | 241 (54.2%)    | 42 (36.8%)     |               |
| Sinovac-CoronaVac      |                |                |                |               |
| Partially vaccinated   | 21 (3.8%)      | 18 (85.7%)     | 3 (14.3%)      | 0.003         |
| Fully vaccinated       | 243 (43.5%)    | 205 (84.4%)    | 38 (15.6%)     |               |
| Pfizer-BioNTech        |                |                |                |               |
| Partially vaccinated   | 30 (5.4%)      | 26 (86.7%)     | 4 (13.3%)      |               |
| Fully vaccinated       | 20 (3.6%)      | 19 (95%)       | 1 (5%)         |               |
| Sinovac plus BioNTech  | 20 (3.6%)      | 17 (85%)       | 3 (15%)        |               |
| By the time between fully vaccinated and illness onset |       |                |                |               |
| 14–120 Days            | 103 (47.6%)    | 83 (34.4%)     | 20 (47.6%)     | 0.118         |
| >120 Days              | 180 (32.4%)    | 158 (65.6%)    | 22 (54.2%)     |               |
| Comorbidities          |                |                |                |               |
| Absent                 | 195 (34.9%)    | 171 (88.4%)    | 24 (21.1%)     | 0.001         |
| Present                | 364 (65.1%)    | 274 (61.6%)    | 90 (78.9%)     |               |
| Comorbidities          |                |                |                |               |
| Hypertension           | 208 (37.2%)    | 152 (34.2%)    | 56 (40.1%)     | 0.003         |
| Diabetes               | 174 (31.1%)    | 131 (29.4%)    | 43 (37.7%)     | 0.088         |
| COPD                   | 77 (13.8%)     | 55 (12.4%)     | 22 (19.3%)     | 0.055         |
| Cardiovascular disease | 29 (5.2%)      | 18 (6%)        | 11 (38%)       | 0.016         |
| Chronic kidney disease | 41 (7.3%)      | 23 (5.2%)      | 18 (35.8%)     | <0.001        |
| Malignancy             | 24 (4.3%)      | 17 (3.8%)      | 7 (6.1%)       |               |
| Hospitalization        |                |                |                |               |
| ICU                    | 168 (30.1%)    | 54 (12.1%)     | 114 (100%)     | <0.001        |
| Non-ICU                | 391 (69.9%)    | 391 (87.9%)    | 0 (0%)         |               |
| Length of stay in hospital wards, median IQRs, day | | | | |
| 6–11                   | 110 (49.2%)    | 86 (43%)       | 24 (12%)       | 0.113**       |
| Length of stay in ICU, median IQRs, day | 7 (3–13)      | 7 (5–12)       | 7 (3–14)       | 0.583**       |

Other p values calculated by chi-square test.
* p = Independent sample t-test.
** p = Mann-Whitney U test.
suggest that the COVID-19 vaccine may help control the pandemic and death for all age groups, including the alpha variant. These findings were significant (OR = 2.84; 95% CI = 2.06, 3.92) and death (OR = 1.39; 95% CI = 1.05, 1.86). In our study, age older than 65, unvaccinated, and comorbidities had significantly higher mortality. In multivariate regression analyses, age, vaccination status, comorbidities and the male gender was associated with mortality.

Increasing age and comorbidities are among independent predictors of mortality in COVID-19 patients. It is thought that immune cell defects that increase with age may cause an above-normal inflammatory response, leading to higher mortality in the elderly [7-9]. In our study, the mortality rate was significantly higher in patients over 65 years of age and with comorbidities. The higher mortality rate in comorbidities may be explained by lower vaccine efficacy and the risk of exacerbating comorbidity after infection or both.

A global meta-analysis of 3 million people reported that while there was no difference in the proportions of men and women with confirmed COVID-19, higher admission rates to the intensive care unit (OR = 2.84; 95% CI = 2.06, 3.92) and death (OR = 1.39; 95% CI = 1.13, 1.47) in men than women [10]. In our study, male patients had almost two times the odds of mortality (OR, 1.8; 95% CI, 1.1-2.9).

A study conducted in Israel showed that two doses of Pfizer-BioNTech vaccine significantly reduced hospitalizations, severe illness and death for all age groups, including the alpha variant. These findings suggest that the COVID-19 vaccine may help control the pandemic and reduce ED visits [4]. In our study, only 50.6% of the patients were fully vaccinated; this finding emphasizes the importance of the vaccine.

As of March 2021, three variants are considered variants of concern (VOCs); Alpha (B.1.1.7), Beta (B.1.351) and Gamma (P.1) SARS-CoV-2 variant. A matched cohort study examining 813 viral genomes showed that Pfizer–BioNTech vaccine efficacy against B.1.1.7 and B.1.351 variants decreased in a certain time window [11]. The B.1.617.2 variant, which causes an increase in Covid-19 cases, especially in India and England, has been detected worldwide. The effectiveness of the CoronaVac and Pfizer–BioNTech vaccines against the B.1.617.2 variant is uncertain [12]. VOCs are spread throughout Turkey; also, the B.1.1.7 variant continues to cause more than half of new COVID-19 cases in Turkey [13].

Vaccine efficacy was not evaluated in our study. However, a statistically significantly lower mortality rate was observed in those fully vaccinated with CoronaVac and Pfizer–BioNTech. In addition, there was no significant difference in mortality rates in terms of variants in the vast majority of patients with the B.1.1.7 variants.

Mortality rates in cohort studies of vaccinated and unvaccinated hospitalized COVID-19 patients were similar [9,14,15]. Parallel to these studies, the mortality rate in all patients was around 20% in our study. However, the mortality rate in unvaccinated patients was statistically higher in our study.

A recent comprehensive study in Qatar showed that the protection of the Pfizer-BioNTech vaccine increases rapidly after the first dose, peaks in the first month after the second dose, and gradually declines over the following months. However, the Pfizer-BioNTech vaccine was effective for up to six months in protection against hospitalization and death [16]. There is no evidence suggesting that vaccines’ effectiveness in preventing hospitalization and death decreases over time. It has also been shown that recurrent infections in vaccinated persons are less contagious than primary infections in unvaccinated persons [16,17]. Our study grouped the time elapsed after the second dose of vaccine as 120 days (four months) and 14–120 days. However, there was no difference in mortality between these two groups (p = 0.118).

The main limitations of our study include its retrospective design, short follow-up period, and assessment of hospitalized patients only. Another limitation of the study; we only examined moderate and severe patients, and mild patients were not included because we could not access their information. Other limitations include the chart abstractors were not trained before data collection, abstractors were not blinded to the study objectives, abstractors’ performance was not monitored, and abstractor interrater-reliability was not assessed.

5. Conclusion

In our study, age older than 65, unvaccinated, and comorbidities had significantly higher mortality. In multivariate regression analyses, age, vaccination status, comorbidities and the male gender was associated with mortality. Male patients and comorbidities had almost two times

### Table 2
The vaccination status by age groups.

| No. of cases, by age group (yrs) | < 65 | ≥65 | Total | p-Value |
|--------------------------------|------|-----|-------|---------|
| Vaccination status             |      |     |       |         |
| Not vaccinated                 | 178  | 47  | 225   | <0.001  |
| Partially vaccinated           | 37   | 14  | 51    | 0.91    |
| Fully vaccinated               | 67   | 216 | 283   | 0.56    |
| Vaccinated patients, by vaccine product |      |     |       |         |
| Sinovac-CoronaVac              | 61   | 203 | 264   | <0.001  |
| Partially vaccinated           | 12   | 9   | 21    | 0.83    |
| Fully vaccinated               | 40   | 194 | 234   | 0.35    |
| Pfizer-BioNTech                | 39   | 11  | 50    | 0.89    |
| Partially vaccinated           | 25   | 5   | 30    | 0.54    |
| Fully vaccinated               | 14   | 6   | 20    | 0.36    |
| Sinovac plus BioNTech          | 4    | 16  | 20    | 0.36    |

### Table 3
Univariate and multivariate logistic regression analysis for mortality.

| Factors             | Unadjusted OR (95% CI) | p-Value | Multivariate logistic regression analysis | Adjusted OR (95% CI) | p-Value |
|---------------------|------------------------|---------|----------------------------------------|----------------------|---------|
| Age in years        |                        |         |                                        |                      |         |
| Age groups          |                        |         |                                        |                      |         |
| < 65                | 1.02 (1.01–1.04)        | <0.001  | 1.05 (1.03–1.08)                      | <0.001              |         |
| ≥ 65                | Reference              | 0.003   | Reference                              | 0.91                | 0.001   |
| Gender              |                        |         |                                        |                      |         |
| Female              | 1.9 (1.25–2.9)         | 0.010   | Reference                              | 0.94 (0.4–2.1)      | 0.008   |
| Male                | Reference              | 0.101   | Reference                              | 0.99 (0.47–1.97)    | 0.008   |
| Comorbidities       |                        |         |                                        |                      |         |
| Absent              | Reference              | 0.001   | Reference                              | 0.99 (0.68–1.47)    | 0.018   |
| Present             | 2.3 (1.3–3.8)          | 0.017   | Reference                              | 0.89 (0.5–1.5)      | 0.018   |
| Vaccination         |                        |         |                                        |                      |         |
| Not vaccinated      | Reference              | 0.39    | Reference                              | 0.24 (0.09–0.60)    | 0.003   |
| Partially vaccinated| 0.42 (0.27–0.66)       | <0.001  | Reference                              | 0.1 (0.05–0.18)     | <0.001  |
| Fully vaccinated    | 0.41 (0.27–0.67)       | <0.001  | Reference                              | 0.1 (0.05–0.18)     | <0.001  |
the odds of mortality. Vaccine efficacy was not evaluated in our study. But lower mortality rate was observed in those fully vaccinated with CoronaVac and Pfizer–BioNTech. Alpha, Delta and other variants had the same mortality rates.

Financial disclosure

This research did not receive any specific grant from funding agencies in the public, commercial, or not-for-profit sectors.

Declaration of Competing Interest

None.

References

[1] Organization WH. Coronavirus (COVID-19) dashboard. World Health Organization; 2021.
[2] Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. New Engl J Med. 2020 Dec 31;383(27):2603–15.
[3] Tanriover MD, Doğanay HL, Akova M, Güner HR, Azap A, Akhan S, et al. Efficacy and safety of an inactivated whole-virion SARS-CoV-2 vaccine (CoronaVac): interim results of a double-blind, randomised, placebo-controlled, phase 3 trial in Turkey. Lancet. 2021 Jul 17;398(10296):213–22.
[4] Haas EJ, Angulo FJ, McLaughlin JM, Anis E, Singer SR, Khan F, et al. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data. Lancet. 2021 May 15;397(10287):1819–29.
[5] Vasileiou E, Simpson CR, Shi T, Kerr S, Agrawal U, Akbari A, et al. Interim findings from first-dose mass COVID-19 vaccine roll-out and COVID-19 hospital admissions in Scotland: a national prospective cohort study. Lancet. 2021 May 1;397(10285):1646–57.
[6] Clinical Spectrum of SARS-CoV-2 Infection. COVID-19 treatment guidelines. National Institute of Health; 2021.
[7] Imam Z, Odish F, Gill T, O’Connor D, Armstrong J, Vanoud A, et al. Older age and comorbidity are independent mortality predictors in a large cohort of 1305 COVID-19 patients in Michigan, United States. J Intern Med. 2020 Oct;288(4):469–76.
[8] Richardson S, Hirsch JS, Narasimhan M, Crawford JM, McGinn T, Davidson KW, et al. Presenting characteristics, comorbidities, and outcomes among 5700 patients hospitalized with COVID-19 in the New York City area. JAMA. 2020 May 26;323(20):2052–9.
[9] Petrelli CM, Jones SA, Yang J, Rajagopalan H, O’Donnell L, Chernyak Y, et al. Factors associated with hospital admission and critical illness among 5270 people with coronavirus disease 2019 in New York City: prospective cohort study. BMJ. 2020 May 22;369:m1966.
[10] Peckham H, de Gruijter NM, Raine C, Radziszewska A, Ciurtin C, Wedderburn LR, et al. Male sex identified by global COVID-19 meta-analysis as a risk factor for death and ITU admission. Nat Commun. 2020 Dec 9;11(1):6317.
[11] Kustin T, Harel N, Finkel U, Perchik S, Harari S, Tahor M, et al. Evidence for increased breakthrough rates of SARS-CoV-2 variants of concern in BNT162b2-mRNA-vaccinated individuals. Nat Med. 2021 Aug;27(8):1379–84.
[12] Lopez Bernal J, Andrews N, Gower C, Gallaghe R, Simmons R, Thelwall S, et al. Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant. New Engl J Med. 2021 Aug 12;385(7):585–94.
[13] Sipuksi MA, Tuyji-Tok Y, Nohut OK, Abülkayyeva Z, Yücebağ E, Can F, et al. First report of SARS-CoV-2 gamma variant in Turkey. Infect Dis Clin Microbiol. 2021:297–9.
[14] Brosh-Nissimov T, Orenbuch-Harroch E, Chowers M, Elbaz M, Neshet L, Stein M, et al. BNT162b2 vaccine breakthrough: clinical characteristics of 152 fully-vaccinated hospitalized COVID-19 patients in Israel. Clin Microbiol Infect. 2021 Nov 1;27(11):1652–62.
[15] Karagianidou C, Mostert C, Hentschker C, Voshaar T, Malzahn J, Schilling G, et al. Case characteristics, resource use, and outcomes of 10 021 patients with COVID-19 admitted to 920 German hospitals: an observational study. Lancet Respir Med. 2020 Sep 1;8(9):853–62.
[16] Chemaitelly H, Tang P, Hasan MR, AlMukdad S, Yasmine HM, Berslimane FM, et al. Waning of BNT162b2 vaccine protection against SARS-CoV-2 infection in Qatar. N Engl J Med. 2021.;385:e83.
[17] Abu-Raddad LJ, Chemaitelly H, Ayoub HH, Tang P, Coyle P, Hasan MR, et al. Effect of vaccination and of prior infection on infectiousness of vaccine breakthrough infections and reinfections. medRxiv. 2021. (2021.07.28.21261086).